Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business – Read more

  • MyriadPro Login
  • Register
  • English
Myriad Logo
  • Patients
    • Patient Guides
      • EndoPredict
      • MyChoice
      • Prolaris
  • Clinicians
    • Patient Care
      • Assessing prognosis
        • EndoPredict
        • Prolaris
      • Precision medicine
        • MyChoice
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Predicting disease
        • MyRisk
    • Resources
      • Publications
      • EndoPredict app
      • Order a test -WIP
      • Case studies (new)
      • Clinical trials (new)
  • Pathologists
    • Pathologists & Labs
      • EndoPredict
      • Become a lab partner
    • Test report generators
      • EndoPredict
        • EndoPredict Report Generator 1
        • EndoPredict Report Generator 2
      • Prolaris
        • Prolaris Biopsy Report Generator
  • Our Tests
    • Myriad’s Tests
      • Breast cancer
        • EndoPredict
      • Prostate cancer
        • Prolaris
      • Ovarian cancer
        • MyChoice
        • MyChoice CDx (Japan)
        • MyChoice HRD Plus (new)
      • Hereditary cancer testing
        • MyRisk
        • MyRisk Plus (Europe – NEW)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Carrier scan
        • Foresight
      • Order a test
      • Technical specifications
  • About
    • About Myriad Genetics
      • Myriad History
      • Join the team
      • Legal Notice
    • News & Events
      • News center
      • Events
      • Newsletter signup
      • Press releases
    • Locations
      • Find a pathology lab (new)
      • Myriad and distributors
  • Contact Us
    • Offices
      • Corporate Offices
      • International Offices
      • Locations
    • Address
      • Myriad Genetics GmbH
        Leutschenbachstrasse 95
        8050 Zurich, Switzerland
    • Email
      • info@myriadgenetics.eu
    • Contact Form
  • Patients
    • Patient Guides
      • EndoPredict
      • MyChoice
      • Prolaris
  • Clinicians
    • Patient Care
      • Assessing prognosis
        • EndoPredict
        • Prolaris
      • Precision medicine
        • MyChoice
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Predicting disease
        • MyRisk
    • Resources
      • Publications
      • EndoPredict app
      • Order a test -WIP
      • Case studies (new)
      • Clinical trials (new)
  • Pathologists
    • Pathologists & Labs
      • EndoPredict
      • Become a lab partner
    • Test report generators
      • EndoPredict
        • EndoPredict Report Generator 1
        • EndoPredict Report Generator 2
      • Prolaris
        • Prolaris Biopsy Report Generator
  • Our Tests
    • Myriad’s Tests
      • Breast cancer
        • EndoPredict
      • Prostate cancer
        • Prolaris
      • Ovarian cancer
        • MyChoice
        • MyChoice CDx (Japan)
        • MyChoice HRD Plus (new)
      • Hereditary cancer testing
        • MyRisk
        • MyRisk Plus (Europe – NEW)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Carrier scan
        • Foresight
      • Order a test
      • Technical specifications
  • About
    • About Myriad Genetics
      • Myriad History
      • Join the team
      • Legal Notice
    • News & Events
      • News center
      • Events
      • Newsletter signup
      • Press releases
    • Locations
      • Find a pathology lab (new)
      • Myriad and distributors
  • Contact Us
    • Offices
      • Corporate Offices
      • International Offices
      • Locations
    • Address
      • Myriad Genetics GmbH
        Leutschenbachstrasse 95
        8050 Zurich, Switzerland
    • Email
      • info@myriadgenetics.eu
    • Contact Form

News Center

News Center
  • Category
    • All
    • Myriad Logos
    • Patients
    • Pipeline
    • Products
    • Providers
    • Uncategorized

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening

December 4, 2019

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening SALT LAKE CITY, Dec. 04, 2019 (...

Continue Reading

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium

December 3, 2019

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium SALT LAKE CITY, Dec. 03, 2019 (GLOBE NEWSWIRE) -- M...

Continue Reading

The American College of Rheumatology Includes the Vectra® Test in New Recommendations on Disease Activity Measures for Rheumatoid Arthritis

November 20, 2019

The American College of Rheumatology Includes the Vectra® Test in New Recommendations on Disease Activity Measures for Rheumatoid Arthritis SALT LAKE CITY, Nov...

Continue Reading

Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening

November 11, 2019

New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy Clinical Study Shows Prequel...

Continue Reading

New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis

November 9, 2019

New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis Vectra Test Predicts Radiographic Progression an...

Continue Reading

Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting

November 1, 2019

Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting SALT LAKE CITY, Nov. 01, 2019 (GLOBE NEWSWIRE) -- M...

Continue Reading

Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting

October 28, 2019

Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting SALT LAKE CITY, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Myr...

Continue Reading

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting

October 8, 2019

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting SALT LAKE CITY, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Myriad G...

Continue Reading

Myriad Announces Research Collaboration with University of Leeds

September 16, 2019

Myriad Announces Research Collaboration with University of Leeds Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer SALT LAKE ...

Continue Reading

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment

September 5, 2019

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment 65 Percent of Patients Remained on Active Surveillance for More than Four Yea...

Continue Reading
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

info@myriadgenetics.eu

Myriad Genetics GmbH
Claridenstrasse 35
8002 Zurich, Switzerland

  • Contact Us
  • Terms of Use
  • Legal Notice
  • Myriad Genetics, Inc. Privacy Policy
  • Cookie Preferences
linkedin twitter instagram youtube

Health. Illuminated.™

  • © 2025 Myriad Genetics, Inc.

Locations

United States
Europe
Japan